Search
forLearn
5 / 801 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn ACETYL TETRAPEPTIDE-2
learn oligopeptide-71
Research
5 / 1000+ resultsresearch D’orenone blocks polarized tip growth of root hairs by interfering with the PIN2‐mediated auxin transport network in the root apex
D'orenone stops root hair growth by disrupting auxin transport, but adding auxin can reverse this.
research Auxin and ethylene: collaborators or competitors?
Auxin and ethylene hormones both work together and against each other to control plant growth.
research A review of the sources and pharmacological research of morroniside
Morroniside has many health benefits, including protection against diabetes complications, bone and brain diseases, heart and skin issues, and it supports hair growth and reduces inflammation.
research Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection
Dextran sulfate was found to be toxic and ineffective for treating HIV.
research Modulation of Macrophage Function by Bioactive Wound Dressings with an Emphasis on Extracellular Matrix-Based Scaffolds and Nanofibrous Composites
Bioactive wound dressings can improve healing by promoting beneficial macrophage activity.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.